Related references
Note: Only part of the references are listed.Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat
Ryan R. G. Barrett et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2022)
Mutations of MSH5 in nonobstructive azoospermia (NOA) and rescued via in vivo gene editing
Min Chen et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
Discovery and mechanism of action studies of 4,6-diphenylpyrimidine-2-carbohydrazides as utrophin modulators for the treatment of Duchenne muscular dystrophy
Aini Vuorinen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease
Zoe R. Maylin et al.
TRANSLATIONAL ONCOLOGY (2021)
Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
Fuqiang Ban et al.
CANCERS (2021)
Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor
Marianne D. Sadar
EXPERT OPINION ON DRUG DISCOVERY (2020)
Simple Syntheses of New Pegylated Trehalose Derivatives as a Chemical Tool for Potential Evaluation of Cryoprotectant Effects on Cell Membrane
Karel Pomeisl et al.
MOLECULES (2020)
The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression
Zhenghong Li et al.
TRANSLATIONAL ONCOLOGY (2020)
Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6
F. Javier Perez-Areales et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer
Yukiyoshi Hirayama et al.
MOLECULAR ONCOLOGY (2020)
Bifunctional HDAC Therapeutics: One Drug to Rule Them All?
Joshua P. Smalley et al.
MOLECULES (2020)
Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
Simon Linder et al.
ENDOCRINE-RELATED CANCER (2019)
Allosteric Targeting of Aurora A Kinase Using Small Molecules: A Step Forward Towards Next Generation Medicines?
Resmi C. Panicker et al.
CURRENT MEDICINAL CHEMISTRY (2019)
503PEPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
R Le Moigne et al.
ANNALS OF ONCOLOGY (2019)
Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies
Jon K. Obst et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2019)
A bioorthogonal turn-on fluorescent strategy for the detection of lysine acetyltransferase activity
Maomao He et al.
CHEMICAL COMMUNICATIONS (2018)
Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
Jemilat Salami et al.
COMMUNICATIONS BIOLOGY (2018)
Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer
Namrata Khurana et al.
ONCOLOGY REPORTS (2017)
EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor
Eva De Mol et al.
ACS CHEMICAL BIOLOGY (2016)
Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer
Yu Chi Yang et al.
CLINICAL CANCER RESEARCH (2016)
The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide
Stefan Prekovic et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
Emmanuel S. Antonarakis et al.
ONCOLOGIST (2016)
Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
Christine Henzler et al.
NATURE COMMUNICATIONS (2016)
EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer
Lucas J. Brand et al.
ONCOTARGET (2015)
The first thiol-yne click chemistry approach for the preparation of liquid crystalline elastomers
Daniele Martella et al.
JOURNAL OF MATERIALS CHEMISTRY C (2015)
Novel drugs targeting the androgen receptor pathway in prostate cancer
Joaquin Mateo et al.
CANCER AND METASTASIS REVIEWS (2014)
Comparative Genomic and Transcriptomic Analyses of LNCaP and C4-2B Prostate Cancer Cell Lines
Lien Spans et al.
PLOS ONE (2014)
An androgen receptor N-terminal domain antagonist for treating prostate cancer
Jae-Kyung Myung et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Synthesis and biological evaluation of triazole-containing N-acyl homoserine lactones as quorum sensing modulators
Danielle M. Stacy et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2013)
Long Terminal Repeats Act as Androgen-Responsive Enhancers for the PSA-Kallikrein Locus
Mitchell G. Lawrence et al.
ENDOCRINOLOGY (2012)
Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
Raymond J. Andersen et al.
CANCER CELL (2010)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: Implications for the androgen receptor functions and regulation
F Alimirah et al.
FEBS LETTERS (2006)
Characterization of C4-2 prostate cancer bone metastases and their response to castration
J Pfitzenmaier et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Share Paper
